Edition:
India

Biohaven Pharmaceutical Holding Company Ltd (BHVN.N)

BHVN.N on New York Stock Exchange

46.89USD
20 Sep 2019
Change (% chg)

$-0.81 (-1.70%)
Prev Close
$47.70
Open
$47.52
Day's High
$47.52
Day's Low
$46.17
Volume
877,271
Avg. Vol
205,358
52-wk High
$67.86
52-wk Low
$29.17

Latest Key Developments (Source: Significant Developments)

Biohaven Announces Pricing Of $300 Million Public Offering Of Common Shares
Wednesday, 19 Jun 2019 

June 18 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd ::BIOHAVEN ANNOUNCES PRICING OF $300 MILLION PUBLIC OFFERING OF COMMON SHARES.SAYS PUBLIC OFFERING OF 6.98 MILLION COMMON SHARES PRICED AT $43.00PER SHARE.  Full Article

Biohaven Pharmaceutical Holding Company Ltd Files For Potential Mixed Shelf Offering; Size Not Disclosed
Tuesday, 18 Jun 2019 

June 17 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd ::BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING.  Full Article

Biohaven Pharmaceutical Holding Co Announces Proposed Public Offering Of Common Shares
Tuesday, 18 Jun 2019 

June 17 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd ::BIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES.BIOHAVEN PHARMACEUTICAL HOLDING COMPANY - COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $300 MILLION OF ITS COMMON SHARES.  Full Article

Biohaven Pharmaceutical Is Exploring A Sale- The Fly, Citing Bloomberg
Friday, 12 Apr 2019 

April 12 (Reuters) - :BIOHAVEN PHARMACEUTICAL IS EXPLORING A SALE AFTER ATTRACTING TAKEOVER INTEREST FROM POTENTIAL BUYERS- THE FLY, CITING BLOOMBERG.  Full Article

Biohaven Pharmaceutical Secures PRV To Expedite Regulatory Review Of Rimegepant Zydis ODT New Drug Application
Monday, 18 Mar 2019 

March 18 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd ::BIOHAVEN PHARMACEUTICAL - SECURES PRV TO EXPEDITE REGULATORY REVIEW OF RIMEGEPANT ZYDIS ODT NEW DRUG APPLICATION.BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD - ENTERED INTO A DEFINITIVE AGREEMENT TO PURCHASE PRV FOR $105 MILLION.BIOHAVEN - IN ADDITION TO PRV DEAL, ALSO RAISING UP TO $200 MILLION IN FINANCING TO BUY PRV AND FOR GENERAL CORPORATE USES.BIOHAVEN PHARMACEUTICAL - FINANCING PROVIDED BY SALE OF PREFERRED SHARES TO ROYALTY PHARMA.BIOHAVEN - ROYALTY PHARMA TO PROVIDE $125 MILLION AT CLOSING, TO ALLOW CO TO DRAW UP TO ADDITIONAL $75 MILLION UPON FDA ACCEPTANCE OF RIMEGEPANT NDA.  Full Article

Biohaven Pharmaceuticals Reports Fourth Quarter And Full Year 2018 Results
Friday, 1 Mar 2019 

Feb 28 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd ::BIOHAVEN PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL AND RECENT BUSINESS RESULTS.BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD QTRLY LOSS PER SHARE $1.33.BIOHAVEN PHARMACEUTICAL - IN MYELOPEROXIDASE INHIBITION PLATFORM, INTEND TO INITIATE PHASE 3 TRIAL OF VERDIPERSTAT IN MULTIPLE SYSTEM ATROPHY IN 3Q2019.BIOHAVEN PHARMACEUTICAL HOLDING - WELL-CAPITALIZED TO CONTINUE DRIVING PROGRESS WITH CASH REACH EXTENDING INTO 4Q2020.BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD - CASH AS OF DECEMBER 31, 2018, WAS $264.2 MILLION.  Full Article

Biohaven Receives FDA May Proceed Letter For Phase 3 Clinical Trial Of Bhv-3241 For Multiple System Atrophy
Wednesday, 23 Jan 2019 

Jan 23 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd ::BIOHAVEN RECEIVES FDA MAY PROCEED LETTER FOR PHASE 3 CLINICAL TRIAL OF BHV-3241 FOR MULTIPLE SYSTEM ATROPHY.EXPECT TO START PHASE 3 TRIAL OF BHV-3241 IN Q3 OF 2019.BIOHAVEN PHARMACEUTICAL HOLDING CO -FDA NOTIFIED CO THAT IT MAY PROCEED WITH ITS CLINICAL INVESTIGATION OF BHV-3241, A NOVEL MYELOPEROXIDASE INHIBITOR.  Full Article

Biohaven Prices Public Offering Of 3.36 Mln Common Shares At $37.25/Share
Thursday, 13 Dec 2018 

Dec 13 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd ::BIOHAVEN ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON SHARES.SAYS PUBLIC OFFERING OF 3.36 MILLION COMMON SHARES PRICED AT $37.25PER SHARE.  Full Article

Biohaven Announces Formation Of Bioshin, A Wholly Owned Asia-Pacific Subsidiary
Thursday, 29 Nov 2018 

Nov 28 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd ::BIOHAVEN ANNOUNCES FORMATION OF BIOSHIN, A WHOLLY OWNED ASIA-PACIFIC SUBSIDIARY.BIOHAVEN PHARMACEUTICAL HOLDING - FORMATION OF BIOSHIN TO DEVELOP, COMMERCIALIZE ITS MIGRAINE, NEUROLOGY PORTFOLIO IN CHINA, OTHER ASIA-PACIFIC MARKETS.BIOHAVEN PHARMACEUTICAL HOLDING - BIOSHIN PLANS TO SUBMIT FIRST INVESTIGATIONAL NEW DRUG APPLICATION TO CHINA FOOD & DRUG ADMINISTRATION BEFORE 2018 END.  Full Article

Biohaven Says Initial Clinical Trial Of BHV-3500 To Explore A Range Of Doses Using Intranasal Administration
Monday, 22 Oct 2018 

Oct 22 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd ::BIOHAVEN RECEIVES AUTHORIZATION TO PROCEED FROM FDA AND DOSES FIRST SUBJECT WITH BHV-3500, THIRD-GENERATION, SMALL MOLECULE CGRP-RECEPTOR ANTAGONIST.BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD - NONCLINICAL PROOF-OF-CONCEPT WITH BHV-3500 HAS BEEN OBSERVED IN A PRIMATE ASSAY.BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD - INITIAL CLINICAL TRIAL OF BHV-3500 WILL EXPLORE A RANGE OF DOSES USING INTRANASAL ADMINISTRATION.  Full Article

Photo

Biohaven's treatment for Lou Gehrig's disease fails to win FDA nod

Biohaven Pharmaceutical Holding Co Ltd said on Friday the U.S. health regulator failed to approve its treatment for amyotrophic lateral sclerosis, or Lou Gehrig's disease, sending its shares down nearly 6% in extended trading.